Wall Street sets UnitedHealth stock price ahead of Q2 earnings report

UnitedHealth (UNH) is under significant pressure heading into its Q2 earnings report on July 29, with shares down 44% year-to-date following Q1 earnings miss, suspended financial guidance, ongoing DOJ probes into billing practices, and higher-than-expected Medicare Advantage claims. Analysts project Q2 revenue to increase 13% year-over-year to $111.88 billion, but adjusted earnings per share are expected to decline to $4.70. Despite these challenges and recent analyst price target reductions reflecting near-term caution, Wall Street maintains a 'Moderate Buy' consensus, with an average 12-month price target of $348.12, suggesting a potential upside of nearly 25%.

Analysis

UnitedHealth (UNH) is approaching its Q2 earnings report under significant duress, marked by a 44% year-to-date decline in its share price. The stock's underperformance is driven by a confluence of negative catalysts from the first half of the year, including an ongoing Department of Justice investigation into its billing practices, a prior suspension of its financial guidance, and the resignation of CEO Andrew Witty. Financially, the company is still grappling with the impact of higher-than-expected Medicare Advantage claims, which led to a Q1 earnings miss and a reduced profit outlook. For the upcoming quarter, consensus estimates project a dichotomy: a robust 13% year-over-year revenue increase to $111.88 billion, but a sharp contraction in adjusted earnings per share to $4.70 from $6.80. Despite these headwinds and the stock trading below the key $300 resistance level, Wall Street maintains a 'Moderate Buy' consensus. This sentiment is tempered by recent analyst actions, such as price target reductions from Wells Fargo and Deutsche Bank, which signal near-term caution regarding regulatory risks and concerns over its Optum Health arm, even while maintaining long-term conviction.

Key Decisions for Investors

• Investors should scrutinize the upcoming Q2 earnings call for any reinstated financial guidance and substantive updates on the DOJ investigation and Medicare Advantage cost trends, as these are the primary overhangs.
• Given the stock's 44% decline against a 'Moderate Buy' consensus with a potential 25% upside, the situation presents a high-risk, high-reward scenario; traders may consider the deep discount an opportunity, while long-term investors should weigh the significant regulatory and earnings risks.
• Monitor the performance and management commentary regarding the Optum Health division, as it has been specifically identified by analysts as the company's biggest area of concern and could be a leading indicator of future challenges.
• Note the recent price target reductions by analysts as a signal of recalibrated near-term expectations, suggesting that even bullish long-term outlooks are being tempered by current headwinds.